Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.01 and traded as low as $0.0009. Nascent Biotech shares last traded at $0.0009, with a volume of 13,000 shares trading hands.
Nascent Biotech Stock Performance
The company’s fifty day moving average is $0.01.
Nascent Biotech Company Profile
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation.
Read More
- Five stocks we like better than Nascent Biotech
- Buy P&G Now, Before It Sets A New All-Time High
- Nike Beats on Earnings But Struggles in China and Faces Tariffs
- The Risks of Owning Bonds
- Is the AI Boom a Bubble? These 2 Dividend Stocks Say No
- Consumer Discretionary Stocks Explained
- 4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
